{"id":"NCT01406938","sponsor":"Novartis Pharmaceuticals","briefTitle":"Efficacy and Safety of Subcutaneous Secukinumab (AIN457) for Moderate to Severe Chronic Plaque-type Psoriasis Assessing Different Doses and Dose Regimens","officialTitle":"A Randomized, Double-blind, Multicenter Study of Subcutaneous Secukinumab, Assessing Psoriasis Area and Severity Index (PASI) Response and Maintenance of Response in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis on Either a Fixed Dose Regimen or on a Retreatment at Start of Relapse Regimen","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-08","primaryCompletion":"2013-05","completion":"2013-05","firstPosted":"2011-08-01","resultsPosted":"2015-05-19","lastUpdate":"2015-05-19"},"enrollment":967,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Moderate to Severe Plaque-type Psoriasis"],"interventions":[{"type":"DRUG","name":"AIN457 150mg","otherNames":["secukinumab 150 mg"]},{"type":"DRUG","name":"AIN457 300mg","otherNames":["secukinumab"]}],"arms":[{"label":"AIN457150 mg- Induction period Only(IPO)","type":"EXPERIMENTAL"},{"label":"AIN457 300 mg - IPO","type":"EXPERIMENTAL"},{"label":"AIN457 150 mg - Fixed Interval (FI)","type":"EXPERIMENTAL"},{"label":"AIN457 300 mg FI","type":"EXPERIMENTAL"},{"label":"AIN457 150 mg- Start of relapse (SoR)","type":"EXPERIMENTAL"},{"label":"AIN457 300 mg- SoR","type":"EXPERIMENTAL"}],"summary":"This study will assess the safety and efficacy of two different doses and two different dose regimens of subcutaneous secukinumab in patients that have moderate to severe, chronic, plaque-type psoriasis.","primaryOutcome":{"measure":"For the Fixed Interval Group and the Start of Relapse (SoR) Group, the Percentage of Participants (Who Responded to Treatment at Week 12) Maintaining a 75% Improvement From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 52","timeFrame":"Week 40 , week 52","effectByArm":[{"arm":"AIN457 150 mg - Fixed Interval (FI)","deltaMin":62.1,"sd":null},{"arm":"AIN457 300 mg FI","deltaMin":78.2,"sd":null},{"arm":"AIN457 150 mg- Start of Relapse (SoR)","deltaMin":52.4,"sd":null},{"arm":"AIN457 300 mg- SoR","deltaMin":67.7,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":9},"locations":{"siteCount":131,"countries":["United States","Austria","Bulgaria","Canada","Czechia","France","Germany","India","Italy","Japan","Poland","Singapore","Slovakia","Switzerland","United Kingdom","Vietnam"]},"refs":{"pmids":["35305260","33748660"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":8,"n":482},"commonTop":["NASOPHARYNGITIS","UPPER RESPIRATORY TRACT INFECTION","HEADACHE","PRURITUS","HYPERTENSION"]}}